FDA approval of higher-dose Ozempic 2 mg

      The US Food and Drug Administration (FDA) has approved a 2 mg dose of Ozempic (semaglutide) injection, a once-weekly glucagon-like peptide-1 (GLP-1) analog to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease. Ozempic will be available in three therapeutic doses (0.5 mg, 1 mg, and 2 mg).

The FDA recently approved the once-weekly injectable Ozempic based on results from the SUSTAIN FORTE clinical trial. The SUSTAIN FORTE clinical trial showed better outcomes over 40 weeks for the 2.0 mg dose compared to the 1.0 mg dose.

Read More